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function in executing fast escape, 
however, the Mauthner system 
has been evolutionarily malleable, 
having been incorporated into 
a range of modified C-start 
behaviours. For example, goldfish 
use C-starts during prey capture 
as well as predator avoidance. 
Similarly, archer fish have evolved a 
dramatic prey capture mechanism, 
whereby the retrieval of insects 
dislodged from vegetation by a 
spit of water involves a C-start 
with the hallmarks of Mauthner 
cell involvement. Recent evidence 
suggests that flying fish become 
airborne using an adapted system 
in which Mauthner cells connect 
to fin adductor motorneurons. In 
contrast to C-starts, however, left 
and right fin motorneurons are 
activated simultaneously, producing 
a sufficiently powerful bilateral fin 
adduction for an aerial escape. A 
similar adaptation occurs in the 
Mauthner cell system of anuran 
amphibians. Whilst in larval stages 
the Mauthner cells mediate classical 
C-starts, the cells atrophy as the tail 
regresses during metamorphosis 
but are retained in limbed juveniles 
to mediate a powerful, synchronous 
contraction of the two hind legs 
in a diving startle response which 
propels them away from danger. 
In conclusion, Mauthner cells have 
evolved to maximize the speed of 
escape and hence optimize survival. 
During evolution, the Mauthner 
system has become incorporated 
into modified escape and predatory 
behaviours suiting the morphological, 
behavioural and ecological 
constraints of the host organism.
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The immune system is arguably 
one of the most complex cellular 
organizations that exists in the body. 
This system is composed of multiple 
cell types that are arranged in distinct 
organs or circulate through the blood 
and peripheral tissues. The complexity 
of the immune system is not 
superfluous, but rather it is required 
to fulfill the multifaceted purpose 
of the immune system, namely: the 
recognition of the diverse repertoire 
of micro-organisms; the detection of 
neoplastic legions originating from a 
range of tissues; and, while executing 
these tasks, the maintenance of 
peripheral tolerance by suppressing 
detrimental responses against healthy 
tissues. Dendritic cells are critical 
players in conducting the immune 
response to fulfill these roles. Here we 
provide an overview of how dendritic 
cells monitor their surrounding 
environment and coordinate an 
appropriate response during both 
steady-state and inflammatory 
conditions. We also highlight some 
of the current approaches aimed to 
harness the unique properties of these 
cells for use as therapeutic agents 
against cancer and infectious disease.
Discovery
The term ‘dendritic’ was first used 
by Ralph Steinman and Zanvil Cohn 
in 1973 to describe a novel cell type 
identified in the secondary lymphoid 
organs of mice. Using microscopy 
techniques, they characterised this 
relatively rare population (~1%) on the 
basis of its adherence properties and 
morphology, with the most striking 
feature being its long cytoplasmic 
processes, which extend and retract 
from the cell body. A physiological 
role for this newly discovered cell type 
was not immediately appreciated. It 
was several years before dendritic 
cells were identified as ‘accessory 
cells’, which demonstrated a capacity, 
greater than that of macrophages, 
Primer to stimulate allogeneic lymphocytes. Another important milestone in the 
understanding of dendritic cell biology 
was the discovery that these cells 
have the ability to present antigen 
on major histocompatibility complex 
(MHC) class I and II molecules. Upon 
migration and maturation, dendritic 
cells become capable of engaging 
lymphocytes and initiating immune 
programs. These observations led 
to dendritic cells being regarded as 
the ‘sentinels’ of the immune system 
and also as ‘professional’ antigen-
presenting cells, for their multiple 
roles in orchestrating immunity. 
Dendritic cell subsets 
Dendritic cells have been 
categorized into multiple subsets 
with the two broadest categories 
being conventional dendritic cells 
(cDCs) and plasmacytoid dendritic 
cells (pDCs). cDCs can be further 
subdivided into distinct populations 
on the basis of their origin, location 
and differential expression of 
surface markers. For example, 
multiple subtypes of cDC exist in 
the skin: the cDCs in the epidermis 
are termed Langerhans cells and 
possess unique structures called 
Birbeck granules; both Langerhans 
cells and dermal dendritic cells (also 
called interstitial dendritic cells) are 
present in the dermal layer; and, 
during inflammatory processes, 
there is infiltration by monocytes that 
may differentiate into a third subset 
of cDCs termed monocyte-derived 
cDCs. Tissue cDCs, such as the three 
mentioned, are typically referred to 
as ‘immature’, on the basis of their 
ability to capture antigen and their 
modest capacity to stimulate T cells. 
Upon activation, these ‘immature’ 
cells may differentiate and migrate via 
the afferent lymphatics into draining 
lymph nodes. Upon maturation, 
cDCs downregulate their ability to 
capture antigen and now possess an 
enhanced ability to stimulate T cells. 
Secondary lymphoid tissues, such as 
lymph nodes and spleen, therefore 
contain migratory tissue cDCs that 
have been stimulated to ‘mature’, but 
they also contain resident populations 
of cDCs that have the ability to 
capture and process internalized 
antigen. Unique functions have been 
ascribed to distinct populations of 
cDCs; however, the overlapping roles 
and diversity of responses are more 
complex than a simple  
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Figure 1. Schematic of the life cycle of dendritic cells, involving interaction with antigen, maturation and migration, and T-cell priming. 
Tissue-resident DCs encounter pathogens in the periphery (1). Inflammatory signals produced in response to recognition of PAMPs engender 
changes in dendritic cells, including the expression of molecules involved in migrating out of tissues, chemokine receptors and co-stimulatory 
molecules. Dendritic cells migrate into the lymphatics (2) and follow chemokine gradients, specifically of the CCR7 ligands CCL19 and CCL21, 
to the T-cell zone of the draining lymph node. Migratory dendritic cells present MHC-I–peptide and MHC-II–peptide complexes derived from cel-
lular and pathogen-associated proteins (3). Lymph node (LN) resident dendritic cell populations process and present antigen that is acquired in 
the lymph node or transferred from migratory dendritic cells. Multiple potential outcomes may result from interactions between naïve T cells and 
dendritic cells (4), including the generation of ‘effector cells’ that develop full CD8+ T-cell activity or cytokine production potential, ‘regulatory’ 
cells that have the ability to modulate the function of other effector cells, and ‘anergic’ cells that are hyporesponsive to antigen and participate 
in maintaining peripheral tolerance.‘1 dendritic cell → 1 function’ 
paradigm. Current efforts in this 
area reveal a coordinated exchange 
between multiple dendritic cell 
subsets throughout the course of an 
immune response (Figure 1). (For an 
in-depth review of the development of 
dendritic cell subsets, see Shortman 
and Naik (2007).)
pDCs represent the second major 
category of dendritic cells and were 
originally called interferon-producing 
cells as they are responsible for the 
robust production of type I interferons 
(IFNs). pDCs circulate through the 
blood, lymph nodes and the spleen 
and, upon stimulation, migrate to the 
T-cell area of lymphoid organs via the high endothelial venules. In addition, 
chronic immune activation may result 
in the recruitment of pDCs to non-
lymphoid tissues. While most studies 
focus on the role pDCs play in bridging 
innate and adaptive immune responses 
in the context of systemic viral or 
bacterial infections, there are also 
reports of pDCs exerting a tolerogenic 
effect on the immune system. Although 
pDCs are interesting in their own right, 
this primer will focus on the role of 
cDCs. (For additional information on 
pDCs, see Gilliet et al. (2008).)
Sensing the microbial biosphere 
Tissue cDCs are an integral part of 
the innate (non-specific) immune response to invading pathogens. 
Their presence in resting tissue, and 
specifically their access to the outside 
environment, enables immature 
cDCs to sense microbial organisms. 
While not unique in their expression 
of pattern recognition receptors 
(PRRs), much attention is afforded 
to how cDCs utilize these receptors 
for engaging pathogen-associated 
molecular patterns (PAMPs), such as 
viral and bacterial nucleic acids, and 
repetitive elements within the viral 
envelope or bacterial cell wall. The 
most well-studied PRRs in humans 
and mice are the Toll-like receptors 
(TLRs), but they also include Nod-
like receptors, RIG-I-like receptors 
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these receptor families is activated by 
distinct agonists at the cell membrane 
or within intracellular vesicles, 
receptor binding initiates signaling 
cascades that result in cDC activation. 
Many of the genes that are involved in 
this transformation are upregulated via 
activation and nuclear translocation 
of the transcription factor NF-κB and 
members of the interferon regulatory 
factor family. Given the differential 
expression of TLRs on cDC subsets, 
we have focused on this family of 
receptors. 
There have been 10 TLRs identified 
in humans (TLR1–10) and 12 in 
mice (TLR1–13, with TLR10 being 
a pseudogene). Broadly, they are 
grouped into the extracellular TLRs, 
which signal at the plasma membrane 
and recognize microbial components 
of the cell wall from fungi, yeast and 
bacteria, and the endosomal TLRs, 
which signal after internalization of 
the ligand and recognize viral and 
bacterial nucleic acids. Engagement 
of TLRs initiates physiological and 
phenotypic changes, including 
the production of chemokines and 
cytokines, many of which can have 
autocrine effects on the cDCs as well 
as paracrine effects on surrounding 
cell types. Differential expression of 
TLRs on cDC populations illustrates 
a molecular segregation of roles for 
the different subsets. For example, 
murine CD8α+ cDCs express TLR3 but 
not TLR5 and are thus able to sense 
organisms that generate double-
stranded RNA but not the flagellum 
proteins produced by certain bacterial 
strains. Human cDCs in the blood 
express all TLRs except for TLR9 and 
are complemented by pDCs, which 
express TLR1, 6, 7, 9 and 10. 
By engaging PRR signaling 
pathways, DCs contribute to the 
innate immune response by secreting 
cytokines, chemokines and other 
bio-active molecules. Production 
of chemoattractants results in 
recruitment of neutrophils, monocytes 
and effector lymphocytes, as well 
as other circulating immune cells. 
Other downstream effects include 
increased permeability of blood 
vessels, which facilitates the entry 
of recruited cells as well as the 
passage of plasma components (e.g. 
complement and antibodies) into the 
site of inflammation. Local stimulation 
of resident lymphocytes, such as 
γδ T cells, natural killer T cells and mucosal-associated invariant T cells, 
can also occur.
PRR activation can also permit 
the induction of anti-microbial 
effectors. While monocytes and 
macrophages are the predominant 
source of reactive oxygen and 
nitrogen species, dendritic cells 
do contribute to the initial innate 
control of pathogens. Specifically, 
interleukin-12 (IL-12) production by 
dendritic cells facilitates activation of 
natural killer cells, which are thought 
to be responsible for the first wave 
of IFNγ secretion. Such feed-forward 
pro-inflammatory cytokine loops are 
implicated in the early response to 
viruses and bacterial infection. 
Bridging the innate and adaptive 
immune response
In addition to innate immune 
programs, PRR activation facilitates 
cDCs in their ability to orchestrate 
adaptive (antigen-specific) immune 
responses. Three critical steps in 
this process are: capture of antigen; 
migration from the tissue into the 
T-cell areas of lymphoid structures; 
and the presentation of internalized 
antigen on MHC molecules. Strikingly, 
TLR activation has been implicated in 
all three of these processes. 
Although a hallmark of cDC 
maturation is the downregulation of 
endocytosis and phagocytosis, recent 
observations indicate that there is a 
transient increase in antigen uptake 
after TLR activation. Mechanistically, 
the increase in antigen uptake is 
associated with membrane-ruffling 
activity. Although TLRs may increase 
antigen capture, these receptors are 
not themselves capable of antigen 
internalization. Instead unique 
receptors enable the internalization of 
various potential sources of antigen, 
such as soluble protein, immune 
complexes, exosomes and dying 
cells. Regarding the specific receptors 
utilized for internalization, we again 
bump into the question of cDC subsets. 
Members of the Fc receptor (FcR) 
family, which bind to antibodies 
attached to invading microbes 
or infected cells, are differentially 
expressed on both human and mouse 
cDC subsets, thus distinguishing 
their handling of immune complexes 
undergoing internalization. For 
example, human blood cDC 
populations differ in their expression 
of the FcRs CD32, CD64 and FcεRI. 
Also, like other human cDC subsets, Langerhans cells express CD32 
constitutively; however, in the presence 
of IL-4 they can be induced to express 
CD23b. Various C-type lectins and 
integrin receptors, which are both 
implicated in antigen capture, are also 
differentially expressed. Clec9A and 
αVβ5 integrin are interesting examples, 
as their expression on the CD8+ cDC 
subset in mice and BDCA-3+ cDCs 
in humans may contribute to the 
efficiency of these cells in the capture 
of dying cells. 
A unique characteristic of tissue-
resident cDCs is their ability to migrate 
via the afferent lymphatics into the T-cell 
zone of the lymph node. This highlights 
a major difference between cDCs and 
macrophages, as macrophages cannot 
migrate out of inflamed tissues. The 
ability of cDCs to migrate from the 
site of infection to the draining lymph 
node is controlled by expression of 
chemokine receptors on their surface. 
Again, we find an important role for 
PRRs in stimulating cDC migration. For 
example, following NF-κB activation, 
the chemokine receptor CCR7 is 
upregulated on maturing DCs, directing 
movement along gradients of its 
chemokine ligands CCL19 and CCL21 
that are established by high endothelial 
venules and stromal cells within the 
lymph node.
To say that PRRs are preparing 
cDCs for engagement of T cells is 
an oversimplification of the biology. 
In fact, activation of NF-κB results in 
the differentiation of cDCs into what 
could be considered a distinct cell 
type, with transcriptional changes 
on the order of thousands of genes 
and as yet unknown translational and 
post-translational modifications. In 
addition to stimulating a transient 
wave of antigen uptake and enabling 
cell migration, many other alterations 
facilitate the processing and 
presentation of antigen. Critical for 
antigen processing are: activation 
of pathways involved in acidification 
and alkylation of endosomes and 
phagolysosomes; protease activation, 
which mediates not only antigen 
processing but also regulates loading 
of MHC class II molecules; and the 
formation of dendritic cell aggresome-
like induced structures and the 
modification of ubiquitin conjugation. 
Orchestrating the adaptive immune 
response
In considering the role of cDCs 
in engaging the adaptive immune 
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Figure 2. Major pathways involved in generating MHC-I–peptide complexes from endogenous 
and exogenous antigen. 
MHC class I presentation of peptides derived from endogenous antigens is termed ‘direct 
presentation’ (pathway 1, red arrows). This process involves digestion of proteins in the cytosol 
(cellular or pathogen-derived) by the proteasome or immunoproteasome complex. These pep-
tides are transferred into the endoplasmic reticulum (ER) where they are bound to MHC class 
I molecules and shuttled through the Golgi complex to the cell surface. Cross-presentation of 
antigen is the process whereby epitopes from exogenous antigen are bound to MHC class I 
molecules (pathway 2, blue arrows). Exogenous antigen is phagocytosed by the cell and the 
phagosome is fused with vesicles derived from the ER. Phagocytosed proteins are retrotrans-
located via SEC61 out of the phagosomes into the cytosol where they can be degraded by 
proteasomes. Processed antigens are transported via the transporter associated with antigen 
processing (TAP) back into the phagosome–ER fusion where they are bound to MHC class I 
molecules and shuttled to the cell surface.system, it is important to note that, 
in many regards, they are not unique. 
All nucleated cells have the capacity 
to present antigen on MHC class 
I molecules via the endogenous 
pathway and part of the definition 
of an APC is the ability to present 
antigen on MHC class II molecules via 
the exogenous pathway (Figure 2).  
These two pathways have been 
considered to be the cornerstone for 
immune surveillance of intracellular 
and extracellular microorganisms, 
respectively. Regarding the unique 
properties of cDCs, it warrants mentioning that, in addition to 
the expression of conventional 
proteasome subunits that are 
important for MHC class I antigen 
processing, some cDC subsets 
constitutively express alternative 
subunits, such as LMP2, LMP7 and 
MECL-1. These molecules define 
the consensus motifs for protein 
cleavage by the immunoproteasome, 
and, as a result, generate a distinct 
repertoire of peptide epitopes for 
presentation by cDCs, which may be 
important in inflammatory situations, 
assuming that immunoproteasome expression has been triggered in 
target cells. Alternatively, expression 
of the immunoproteasome may 
allow for cDCs to have their own 
relationship with a subset of 
antigen-specific T cells. Unique 
aspects are also involved in the 
presentation of exogenous antigen. 
For example, cDCs and macrophages 
show differences in the timing of 
phagosome acidification, which 
influences the balance between 
antigen processing and protein 
degradation. This translates into an 
increased efficiency of generating 
MHC class II–peptide complexes 
within cDCs. 
Two other antigen presentation 
pathways have been identified. 
cDCs are capable of processing and 
presenting internalized exogenous 
antigen onto their own MHC class I 
molecule. While initially overlooked 
as a minor pathway, it is now clear 
that this mechanism accounts for the 
presentation of antigens derived from 
many viruses that do not themselves 
infect hematopoietic cells, antigens 
that are unique to cells undergoing 
malignant transformation or donor 
cells from organ transplantation, 
and self antigen that is restricted in 
its expression to non-hematopoietic 
cells. This process is termed 
‘cross-presentation’, for crossing 
the classically defined restriction 
of presenting only endogenously 
produced antigen on MHC class I 
molecules. Certain cDC subsets are 
more efficient in their presentation of 
exogenous antigen, although arguably 
there may be an as yet unappreciated 
complexity regarding the source of 
the antigen (e.g. immune complexes 
versus dying cells) and the receptors 
involved in internalization. It should 
not be overlooked that other cell 
types, such as endothelial cells, have 
the capacity to cross-present antigen. 
Finally, there is the direct presentation 
of endogenous antigen onto MHC 
class II molecules (Figure 3).  
Recent work has established an 
important role for autophagy in the 
delivery of cytosolic antigen into the 
vesicular compartment of antigen-
presenting cells. Although cDCs utilize 
this mechanism, it is too early to say 
whether they are unique in this regard. 
Form does not always dictate 
function and just because a cell 
presents antigen does not mean it can 
initiate a T-cell response. Indeed, this 
is where cDCs rise high above all other 
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as the ‘professional antigen-presenting 
cell’. This term was first coined by 
Polly Matzinger for the ability of cDCs 
to activate naïve T cells, distinguishing 
cDCs from macrophages and B cells, 
which are capable of presenting 
antigen and re-stimulating memory T 
cells but are not capable of initiating 
a priming response. Arguably, cDCs 
may also be unique in their ability to 
initiate peripheral tolerance to a subset 
of tissue-restricted antigens. This latter 
assertion is based on their ability to 
capture antigen and migrate to the 
T-cell areas of draining lymph organs 
for the engagement of naïve T cells. 
As naive T cells do not enter resting 
peripheral tissue, this may be the only 
means of inactivating potentially self-
reactive tissue-specific T cells. 
So, what are the rules for dictating 
the outcome of priming versus 
tolerance? First, some definitions: 
T-cell priming is the result of a series 
of events that include T-cell receptor 
engagement, cell division and the 
acquisition of effector function (e.g. 
cytokine production, cytotoxicity); 
tolerance also involves T-cell receptor 
engagement and it may in some 
cases include cell division (especially 
for CD8+ T cells), but typically these 
cells do not acquire effector function, 
instead undergoing a programmed cell 
death. In the literature, there is much 
discussion of T-cell anergy being 
a mechanism or state of tolerance 
(defined by cells doing nothing); 
however, in many cases it seems that 
such anergic cells do in fact have 
regulatory functions. For the purposes 
of this discussion, we will avoid 
the term ‘activation’ for describing 
lymphocytes as it does not properly 
specify the outcome of antigen 
presentation and T-cell engagement. 
The first rule of T-cell receptor 
engagement is a requirement for 
MHC–peptide complexes on an 
antigen-presenting cell (referred to as 
‘signal 1’). The second rule concerns 
co-stimulatory molecules, such 
as B7-family members (e.g. CD80, 
CD86) on cDCs, engaging CD28 
on T cells (referred to as ‘signal 2’). 
Prior models suggested that signal 
1 in the absence of signal 2 results 
in tolerance, and that signal 1 in the 
presence of signal 2 confers the 
ability to prime an adaptive immune 
response. As such, immature cDCs 
were thought to induce tolerance 
and, upon maturation, which ER
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Figure 3. Major pathways involved in generating MHC-II–peptide complexes from endogenous 
and exogenous antigen. 
For MHC class II presentation of peptides derived from exogenous antigens (pathway 1, or-
ange arrows), exogenous antigen is endocytosed into the cell where it is partially digested 
and incorporated into the MHC-II compartment (MIIC). Potential epitopes compete with class-
II-associated invariant chain (Ii) peptide (CLIP) for binding to the MHC class II molecule (with 
HLA-DM/DO facilitating the removal of CLIP) before transport to the cell surface. The bio-
synthetic pathway of loading MHC class II molecules with endogenous antigens (pathway 2, 
green arrows) involves the formation of MHC-II–peptide complexes where the peptide antigen 
is derived from endogenous proteins. This pathway is initiated by encapsulation of cytosolic 
components (including cellular and pathogen-derived material) by autophagosomes. These 
vesicles are fused with lysosomes, which digest the material, generating potential antigenic 
epitopes that are transported into the MIIC and loaded onto MHC class II molecules.results in the upregulation of co-
stimulatory molecules, cDCs would be 
responsible for priming.
Recent studies indicate that this 
model is flawed in several regards. 
Given that naïve T cells do not traffic 
into resting tissue, tolerance to 
self-antigen must occur in lymphoid 
organs. As such, cDCs are required 
to present that antigen and careful 
cell biological studies indicate 
that maturation is a pre-requisite 
for MHC–peptide presentation of 
tissue-restricted antigen. Further, 
to reach the T-cell area, cDCs must 
upregulate CCR7. Finally, it has 
been demonstrated that, in many experimental systems, co-stimulatory 
molecules are required for T-cell 
tolerance. While the details may differ 
for constitutively expressed versus 
tissue-restricted antigen, it seems 
that TLR activation of cDCs does not 
determine the outcome of an immune 
response. 
Complementing these findings, it 
has been described that cDCs require 
helper signals in order to effectively 
prime CD8+ T cells. Such helper 
signals include CD40L, delivered by 
antigen-specific CD4+ T cells, which 
in turn stimulates the production of 
pro-inflammatory factors, collectively 
referred to as ‘signal 3’.
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Due to the pivotal role that dendritic 
cells have in coordinating the innate 
and adaptive immune responses, 
it is no surprise that pathogens 
have evolved to subvert the role of 
these cells in host immunity. Here, 
we provide examples of the diverse 
and creative strategies adopted by 
microbes to kill, avoid, hijack and 
selectively suppress DC functions. 
Collectively, these various pathogen-
associated countermeasures have 
the capacity to subvert pathogen 
clearance by antigen-specific T cells. 
During infection, the measles 
virus engages cDCs in the 
respiratory mucosa and lymphoid 
organs. A transient but profound 
immunosuppression is observed that 
occasionally results in opportunistic 
infections that are responsible for 
a high rate of mortality in children. 
Strikingly, infection of cDCs with 
measles virus results in syncitia 
formation, which supports high 
replication of the virus. More 
disturbingly, this virus also results 
in the profound death of immature 
DCs, possibly via upregulation 
of the interferon-induced, pro-
apoptotic protein TRAIL. Although 
these phenomena account for early 
immunosuppression, in surviving 
hosts dendritic cells ultimately 
support the priming of virus-specific T 
cells that mediate viral clearance. 
Another mechanism of viral 
immune evasion is characterized by 
Herpesviridae. Members of this family 
have evolved decoy mechanisms that 
allow them to avoid opsonization and 
uptake by cDCs. These mechanisms 
include the production of viral proteins 
that bind complement and antibodies, 
thus blocking receptor-mediated 
phagocytosis. In addition, expression 
of viral cytokines and viral chemokines 
or chemokine receptor antagonists 
participates in the skewing of 
responses to favor viral latency and 
prevent clearance. 
Pathogens can also use cDCs 
to mediate their dissemination. 
An example of this is the ability 
of Toxoplasmosis gondii to infect 
cDCs in the intestinal mucosa and 
alter their migratory properties. 
The aberrant trafficking of cDCs is 
facilitated in part by making them 
insensitive to chemokine gradients 
and also by enhancing their ability 
to cross endothelial barriers. Via as 
yet unknown circulatory pathways, parasitized cDCs are thought to be 
responsible for delivering T. gondii 
to the brain. Interestingly, similar 
strategies may be involved in the 
dissemination of prions. 
Many bacteria have been reported to
subvert cDC function with Mybacteria 
ulcerans being one important 
example. Through the production of 
mycolactone, this pathogen inhibits 
cDC maturation and blocks the 
production of critical pro-inflammatory 
chemokines. 
Maintenance of peripheral tolerance
Although it may be tempting to focus 
solely on the responsibilities that 
dendritic cells have in orchestrating 
responses involved in pathogen 
recognition and clearance, these 
cells also play an essential role in 
maintaining peripheral tolerance 
to self-antigens. One important 
mechanism may include the normal 
turnover that occurs in many tissues 
and allows immature dendritic cells, 
in the steady state, to capture self-
antigen from internalized dying cells 
and, upon maturation, migrate to 
draining lymph nodes and induce 
tolerance in self-reactive T cells. 
In the case of CD4+ T cells, this 
may result in the establishment of 
regulatory cells, and, for CD8+ T 
cells, tolerance is contingent on the 
absence of helper signals. Current 
views suggest that ‘tolerogenic 
dendritic cells’ have the capacity to 
present antigen and engage T cells, 
but do not express inflammatory 
mediators.
Clinical use
As we learn more about the function 
of cDCs in orchestrating immunity, 
it becomes apparent that we can 
also put them to work for our own 
therapeutic interests, especially in 
situations where they may have been 
outwitted by self cells undergoing 
malignant transformation or by 
invading microorganisms. Indeed, 
many therapies have been envisioned 
to harness the selectivity of cDC–T-
cell engagement with the idea of 
arming the adaptive immune system to 
respond to cancer and infected cells. 
We briefly highlight three different 
approaches to utilizing cDCs in clinical 
trials. 
First, cDCs may be isolated and/or 
expanded ex vivo, allowing loading of 
the cDC with target antigen. In cases 
where the antigen and specific MHC  
epitopes have been defined, loading 
may involve pulsing with protein, 
peptide or transfection with antigen-
encoding nucleic acids. Alternatively, 
cDCs can be loaded with dying cells, 
exosomes, complexes of antigen and 
heat shock protein, or cell lysates. 
These approaches are attractive as 
they have the benefit that the precise 
antigen or epitope does not need to 
be known. The cDC does the work in 
processing and presenting the tumor 
or microbial-associated antigen that 
fits that individual’s MHC haplotype. 
Ex vivo maturation and adoptive 
transfer of the antigen-bearing cDCs 
to recipients will ideally prime T-cell 
responses that are capable of rejecting 
tumor cells and clearing infectious 
agents. 
A second approach is aimed at 
in vivo targeting of cDCs. In these 
approaches, known antigens may be 
complexed with targeting vectors, 
such as antibodies selective for cDC 
receptors or viral vectors with tropism 
for cDCs. Finally, the injection of DNA 
or nanoparticles may favor uptake and 
presentation by cDCs. 
Finally, there have been efforts to 
alter the microenvironment in which 
cDC and T-cell interactions occur, 
predicated on the belief that tumor or 
microbial antigens are being presented 
but not in a context that is conducive 
for T-cell priming. The alterations 
to the microenvironment may be 
achieved by influencing three stages 
of cDC differentiation and function: 
certain growth factors are capable of 
selectively differentiating precursors 
toward the DC lineages; chemokines 
have been utilized to recruit distinct 
cDC subsets to the inflammatory site; 
and, by injection of immune adjuvants 
or ‘signal 3’ stimuli, there is the hope of 
promoting effector T-cell priming. 
With each of these cDC-based 
therapies there are pitfalls and 
obstacles that have prevented our 
ability to harness their full potential. 
Through a better understanding of 
disease pathogenesis and optimal 
vaccine strategies, there remains the 
hope of increased clinical applications 
for immune-based treatment. 
Future directions 
The purpose of this primer was 
to outline some of the basic 
characteristics and functions of 
cDCs and how they are involved 
in innate and adaptive immune 
responses. Our understanding of 
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host plant adapted to house the 
ants — more rapidly and in greater 
numbers when an experimentally 
damaged mature leaf was placed 
near the entrance of the domatium 
than when an untreated filter paper 
(n = 31) or an intact mature leaf 
(n = 10) was placed in the same 
position (P < 0.001 in all cases) 
(see Supplemental data available 
on-line with this issue for details). 
The host-protective behaviour 
of P. phylax is thus mediated by 
chemical signals, as would be 
expected from theory and as has 
been demonstrated in many cases 
[2,3,5]. In contrast, for Cataulacus 
mckeyi, a specific ant parasite of 
this mutualism [4], we showed that 
experimentally damaged leaves 
held at the entrance of domatia did 
not induce exit of more ants than 
did filter paper (n = 11). Moreover, 
significantly greater numbers of 
workers of the mutualist P. phylax 
exited domatia in the same situation, 
reflecting variation in the investment 
in protection in different plant-ants 
associated with the same host 
species, a phenomenon that has 
been reported in only a few other 
cases [3].
Signalling herbivore activity confers 
the greatest advantage on a plant 
when the signals reach the ants 
rapidly; selection should thus have 
favoured the production of rapidly 
diffusing compounds. We detected 
three compounds in VOC emissions 
from all experimentally damaged L. 
a. africana mature leaves: methyl 
salicylate, 2E hexen-1-ol, and hexanal. 
These common green leaf volatiles are 
known to play roles in the attraction 
to the plants that produce them of 
natural enemies of phytophagous 
insects [6]. They have also been 
reported to be present in emissions 
from damaged leaves of several Asian 
Macaranga spp. ant-plants [7].
To determine the biologically 
active compounds, we compared 
the reactions of P. phylax to different 
stimuli (filter papers impregnated with 
synthetic compounds) placed near 
domatia entrances (Figure 1). We 
found that the number of ants exiting 
domatia was significantly higher 
for methyl salicylate, 2E hexen-1-ol 
and the mix than for hexanal alone 
and control (Figure 1). There was no 
significant difference between methyl 
salicylate, 2E hexen-1-ol and the mix, 
nor between hexanal and control, 
A simple non-
specific chemical 
signal mediates 
defence behaviour 
in a specialised 
ant–plant 
mutualism
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Specialist ‘plant-ants’ defend their 
ant-plant hosts from herbivores in 
exchange for rewards, including 
shelter and food [1]. Many of these 
symbiotic associations are obligate 
mutualisms, in which ant fitness 
is strongly tied to host protection. 
Protection should be enhanced 
by efficient detection of attacking 
herbivores [1–3]. How information 
about herbivore presence could be 
communicated from plant to ant 
has been little studied. In several 
systems, plant extracts have been 
shown to induce increased ant 
patrolling [2,3], but the compounds 
eliciting ant defence have never been 
identified. We have characterized 
the volatile compounds emitted by 
damaged leaves of a specialized 
ant-plant and demonstrated in field 
experiments the identity of chemicals 
that induce plant-protective 
behaviour. 
The ant Petalomyrmex phylax 
protects Leonardoxa africana 
africana against herbivores [4]. 
Young leaves are constantly 
patrolled; ants visit mature leaves 
to harvest extrafloral nectar [4]. 
Some volatile organic compounds 
(VOCs), including methyl salicylate, 
are emitted constitutively by young 
leaves but not mature leaves [2]. 
Methyl salicylate was not detected 
in 30 minute hexane washes of 
mature leaves [2], but small amounts 
were detected in 2 hour extracts, 
indicating that this compound is 
less concentrated, perhaps also 
differently distributed, in mature 
leaves. We showed that P. phylax 
exited from domatia — sites on the 
Correspondencedendritic cell biology is increasing at a rapid pace. Areas of current 
interest include: the identification 
and characterization of new subsets 
of dendritic cells; advances in intra-
vital microscopy, which facilitates 
real-time observations of cDCs with 
cognate T cells; evaluation of how 
cell death influences dendritic cell 
cross-priming; understanding the 
context in which dendritic cells may 
optimally facilitate the expansion or 
differentiation of regulatory T cells; and 
further identification of endogenous 
activators responsible for dendritic cell 
maturation in the absence of PAMPs. 
These areas of research (and many 
others) hold great promise to advance 
our understanding of how dendritic 
cells orchestrate the immune response 
in health and pathology.
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